Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NEOK002
- Development stage
- Phase 1
- Lead developer
- NEOK Bio
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NEOK002 is a bispecific antibody-drug conjugate (ADC) designed to simultaneously target the epidermal growth factor receptor (EGFR) and mucin 1 (MUC1). Developed by NEOK Bio, Inc., this therapeutic candidate is intended for the treatment of locally advanced or metastatic solid tumors. By dual-targeting EGFR and MUC1—two antigens frequently overexpressed in various epithelial cancers—NEOK002 aims to enhance tumor specificity and overcome resistance mechanisms associated with single-target therapies. The bispecific antibody component facilitates the selective delivery of a cytotoxic payload directly into tumor cells upon internalization. As of 2024, NEOK002 is undergoing Phase 1 clinical evaluation to assess its safety, tolerability, and to determine the recommended dose for expansion (RDE).
02
Targets
EGFR (Epidermal growth factor receptor)MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on NEOK002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEOK002.